Cue Biopharma Files Q1 2025 10-Q, Cites Warrant Activity
Ticker: CUE · Form: 10-Q · Filed: May 12, 2025 · CIK: 1645460
Sentiment: neutral
Topics: 10-Q, biopharma, warrants, licensing
TL;DR
Cue Bio Q1 10-Q out. Lots of warrant action, Einstein deal mentioned. Looks okay.
AI Summary
Cue Biopharma, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly Imagen Biopharma, Inc., is in the pharmaceutical preparations industry. Key financial events and dates mentioned include transactions related to warrants in 2022, 2024, and 2025, and fair value measurements as of December 31, 2024. The filing also references a license agreement with Einstein.
Why It Matters
This filing provides insight into Cue Biopharma's financial health and operational activities during the first quarter of 2025, including details on warrant transactions and licensing agreements.
Risk Assessment
Risk Level: medium — Biopharmaceutical companies often face high risks due to the nature of drug development and regulatory hurdles, though specific details in this filing don't indicate immediate severe distress.
Key Numbers
- 2025-03-31 — Reporting Period End (Covers the first quarter of 2025)
- 2025-05-12 — Filing Date (Date the 10-Q was submitted)
- 2024-12-31 — Fair Value Measurement Date (Indicates financial reporting as of year-end 2024)
Key Players & Entities
- Cue Biopharma, Inc. (company) — Filer
- Imagen Biopharma, Inc. (company) — Former company name
- 20250331 (date) — Reporting period end date
- 20250512 (date) — Filing date
- SiliconValleyBank (company) — Mentioned in relation to a loan
- Einstein (company) — Licensing agreement
FAQ
What was the nature of the warrant activity mentioned in the filing for 2022, 2024, and 2025?
The filing references specific dates like November 16, 2022, September 26, 2024, and general periods in 2025 related to 'TwoThousandTwentyTwoPreFundedWarrantsMember', 'TwoThousandTwentyFourCommonStockWarrantsMember', and 'WarrantMember', suggesting issuance or exercise of warrants.
What is the significance of the 'Einstein License Agreement'?
The filing mentions 'cue:EinsteinLicenseAgreementMember' in the context of the reporting period 2025-01-01 to 2025-03-31, indicating a licensing agreement with an entity named Einstein during this quarter.
What does the mention of 'SiliconValleyBankMember' imply?
The filing includes 'cue:SiliconValleyBankMember' alongside 'cue:TrancheALoanMember', suggesting a loan or financial arrangement with Silicon Valley Bank.
What financial reporting standards are being referenced?
The filing includes references to 'http://fasb.org/us-gaap/2024#LicenseMember', indicating adherence to US GAAP standards for 2024.
What was the company's previous name?
The company was formerly known as Imagen Biopharma, Inc., with a date of name change on June 17, 2015.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding Cue Biopharma, Inc. (CUE).